- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Combination medication amitriptyline+pregabalin is used to treat neuropathic pain. As a result of nerve injury or a dysfunctional nervous system, neuropathic pain is a chronic, progressive nerve illness that causes pain in the nerves.
The pain, which might be stabbing, prickling, tingling, or scorching, may be sporadic or constant.
Pregabalin, an anti-convulsant, and Amitriptyline are combined as amitriptyline+pregabalin (antidepressant). Pregabalin relieves nerve pain by attaching to a specific location on voltage-gated calcium channels.
Amitriptyline boosts serotonin and noradrenaline levels, which slows down the movement of pain receptors. amitriptyline and pregabalin work well together to relieve neuropathic pain.
Certain typical adverse effects, such as weight gain, dry mouth, blurred vision, fatigue, dizziness, nausea, vomiting, diarrhoea, and constipation, may occasionally occur.
The majority of these adverse effects go away gradually over time without the need for medical care. However, if you have these side effects frequently, you should consult your doctor.
If you have recently used MAO inhibitors or if you are allergic to any of the medication's ingredients, do not take amitriptyline+pregabalin.
Before beginning amitriptyline+pregabalin, let your doctor know if you have or have previously had cardiac issues, bipolar disorder, severe liver illness, or porphyria.
If you are expecting or nursing, talk to your doctor. Driving should only be done when you are attentive since amitriptyline+pregabalin may make you drowsy and queasy.
Children shouldn't be administered amitriptyline+pregabalin since its effectiveness and safety have not been shown. amitriptyline+pregabalin should not be taken with alcohol as this may cause increased drowsiness and sleepiness.
Global pregabalin amitriptyline market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
In order to aid consumers and healthcare professionals in understanding and managing neuropathic (nerve) pain, NPS MedicineWise has introduced new tools.
Health practitioners can find resources to aid in the diagnosis of neuropathic pain, such as a downloadable questionnaire and a video tutorial on how to conduct sensory testing to identify radicular back pain
.Additionally, there are recommendations for treating neuropathic pain, prescriptions for amitriptyline and pregabalin, and details on options for continuing professional development.
In addition, amitriptyline is less expensive than pregabalin. As a result, we came to the conclusion that amitriptyline was a better therapy option than pregabalin because it was well tolerated and had a lower price tag given the increased effectiveness.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.